Yonkenafil (hydrochloride)

Yonkenafil (Tunodafil) hydrochloride, a novel phosphodiesterase 5 (PDE5) inhibitor, is effective in reducing cerebral infarction, neurological deficits, edema, and neuronal damage in the infarcted area. Yonkenafil (Tunodafil) hydrochloride may improve cognitive function by modulating neurogenesis and has a potential therapeutic effect on Alzheimer's disease[1].

Product Specifications

CAS Number

[804519-64-0]

Product Name Alternative

Tunodafil (hydrochloride)

UNSPSC

12352005

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/yonkenafil-hydrochloride.html

Concentration

10mM

Purity

99.43

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1C2=C(N=C(N1)C3=CC(S(=O)(N4CCN(CC4)CC)=O)=CC=C3OCC)N(C=C2C)CCC.[H]Cl

Molecular Formula

C24H34ClN5O4S

Molecular Weight

524.08

References & Citations

[1]Xuemei Chen, et al. Yonkenafil: a novel phosphodiesterase type 5 inhibitor induces neuronal network potentiation by a cGMP-dependent Nogo-R axis in acute experimental stroke. Exp Neurol. 2014 Nov;261:267-77.